Adaptive Biotechnologies Corporation
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$15.1M
Doctors Paid
4,631
Transactions
12,960
2024 Total
$1.3M
Payment Breakdown by Category
Research$12.7M (84.2%)
Consulting$1.5M (9.8%)
Food & Beverage$334,357 (2.2%)
Travel$105,054 (0.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $12.7M | 2,421 | 84.2% |
| Consulting Fee | $1.5M | 560 | 9.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $414,878 | 570 | 2.7% |
| Food and Beverage | $334,357 | 9,140 | 2.2% |
| Travel and Lodging | $105,054 | 251 | 0.7% |
| Space rental or facility fees (teaching hospital only) | $44,188 | 16 | 0.3% |
| Grant | $5,750 | 2 | 0.0% |
Payments by Type
Research
$12.7M
2,421 transactions
General
$2.4M
10,539 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| 15-180 | $2.4M | 0 | 26 |
| PREDICT | $801,250 | 0 | 2 |
| NCR202406 | $741,000 | 0 | 1 |
| ImmuneSense Lyme | $600,105 | 0 | 43 |
| ONC1401 | $522,900 | 0 | 11 |
| 18-282 | $521,100 | 0 | 7 |
| PBMTC-ONC-1701 | $471,150 | 0 | 646 |
| 10-106 | $328,950 | 0 | 1 |
| Watch Registry | $304,189 | 0 | 16 |
| Abdel Azim - ONC1701 | $263,850 | 0 | 188 |
| A Phase II Pilot Trial to Estimate Survival After a Non-total Body Irradiation (TBI) Based Conditioning Regimen in Patients Diagnosed With B-acute Lymphoblastic Leukemia (ALL) Who Are Pre-allogeneic Hematopoietic Cell Transplantation (HCT) Next-generation-sequence (NGS) Minimal Residual Disease (MRD) Negative | $249,750 | 0 | 204 |
| 201411060 | $228,600 | 0 | 98 |
| ImmuneSense COVID-19 | $225,350 | 0 | 5 |
| PBMTC GVH 1201 | $208,200 | 0 | 1 |
| The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL | $205,900 | 0 | 190 |
| 19-395 | $201,250 | 0 | 68 |
| 543197 COVAX | $183,000 | 0 | 1 |
| Optimizing ctDNA based MRD assessment in DLBCL, MCL and FL patients undergoing CAR Therapy | $173,603 | 0 | 1 |
| 43067 | $168,750 | 0 | 1 |
| Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy | $168,000 | 0 | 24 |
| 2017-1366 | $157,350 | 0 | 3 |
| CIBMTR SC21-07 / BMT CTN 2101 | $150,000 | 0 | 1 |
| VenetoStop_19-395 | $149,250 | 0 | 150 |
| 201106379 | $147,600 | 0 | 2 |
| 19-0339 | $141,450 | 0 | 103 |
| 06-254 | $139,950 | 0 | 1 |
| Phase 1b/2 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma | $136,200 | 0 | 4 |
| Sequential Assessment of Minimal Residual Disease by Next Generation Sequencing to Optimize Outcomes and Minimize Exposure in Venetoclax-Treated CLL Patients | $133,100 | 0 | 142 |
| 297381-29 | $128,700 | 0 | 3 |
| BMT320 | $127,809 | 0 | 13 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Gaurav Singal, M.d, M.D | Internal Medicine | Boston, MA | $435,158 | $0 |
| Stephan Grupp, M.d, M.D | Pediatrics | Philadelphia, PA | $77,492 | $0 |
| Dr. Nicholas Short, Md, MD | Hematology & Oncology | Houston, TX | $62,045 | $0 |
| Dr. Georges Azzi, M.d, M.D | Hematology & Oncology | Fort Lauderdale, FL | $48,402 | $0 |
| Dr. Jeffrey Wolf, M.d, M.D | Specialist | San Francisco, CA | $47,619 | $0 |
| Ms. Christine Rimkus, Cns, CNS | Oncology | Saint Louis, MO | $44,232 | $0 |
| Elias Jabbour, M.d, M.D | Hematology & Oncology | Houston, TX | $42,102 | $0 |
| Dr. Adriana Rossi, Md, MD | Medical Oncology | New York, NY | $40,264 | $0 |
| Dr. Edward Pearson, Md, MD | Internal Medicine | Dallas, TX | $32,449 | $0 |
| Dr. Rafael Fonseca, M.d, M.D | Hematology | Scottsdale, AZ | $32,368 | $0 |
| Carl Landgren, Md, MD | Hematology & Oncology | Miami, FL | $31,127 | $0 |
| Dr. Joshua Richter, M.d, M.D | Medical Oncology | New York, NY | $29,422 | $0 |
| Javier Pinilla-Ibarz, Md, MD | Internal Medicine | Tampa, FL | $27,689 | $0 |
| Dr. Rushang Patel, M.d, Ph.d, M.D, PH.D | Internal Medicine | Orlando, FL | $27,442 | $0 |
| Ehsan Malek, M.d, M.D | Medical Oncology | Buffalo, NY | $27,333 | $0 |
| Mr. Mohammad Hussaini, Md, MD | Anatomic Pathology & Clinical Pathology | Saint Louis, MO | $26,561 | $0 |
| Anthony Mato, Md, MD | Medical Oncology | Ithaca, NY | $26,327 | $0 |
| Ryan Jacobs, Md, MD | Internal Medicine | Charlotte, NC | $24,953 | $0 |
| Dr. Tara Graff, Do, DO | Medical Oncology | Clive, IA | $23,017 | $0 |
| Dr. Timothy Fenske, Md, MD | Hematology & Oncology | San Antonio, TX | $23,000 | $0 |
| Matthew Davids, M.d, M.D | Hematology & Oncology | Boston, MA | $22,784 | $0 |
| Dr. Dan Douer, M.d, M.D | Hematology | New York, NY | $21,902 | $0 |
| Mihir Raval, M.d. , M.p.h, M.D. , M.P.H | Hematology & Oncology | Albany, NY | $20,549 | $0 |
| Dr. Scott Goldsmith, Md, MD | Internal Medicine | Duarte, CA | $20,476 | $0 |
| Robert Hershberg, Md Phd, MD PHD | Clinical Genetics (M.D.) | Seattle, WA | $20,000 | $0 |
About Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation has made $15.1M in payments to 4,631 healthcare providers, recorded across 12,960 transactions in the CMS Open Payments database. In 2024, the company paid $1.3M. The top product by payment volume is clonoSEQ ($9.2M).
Payments were distributed across 91 medical specialties. The top specialty by payment amount is Internal Medicine ($706,339 to 445 doctors).
Payment categories include: Food & Beverage ($334,357), Consulting ($1.5M), Research ($12.7M), Travel & Lodging ($105,054).
Adaptive Biotechnologies Corporation is associated with 3 products in the CMS Open Payments database.